Brief Reviews |
From the Gonda Diabetes Research Center (R.N.), Beckman Research Institute of City of Hope, Duarte Calif; and the Diabetes and Hormone Center of Excellence (J.L.N.), University of Virginia School of Medicine, Charlottesville, Va.
Correspondence to Dr Rama Natarajan, Gonda Diabetes Research Center, Beckman Research Institute of City of Hope, 1500 East Duarte Road, Duarte, CA 91010. E-mail RNatarajan{at}coh.org; or to Dr Jerry L. Nadler, Diabetes & Hormone Center of Excellence, University of Virginia School of Medicine, 450 Ray C Hunt Drive, Fontaine Medical Research Bldg, Charlottesville, VA 22908. E-mail jln2n{at}virginia.edu
Series Editor: Richard A. Cohen
ATVB in Focus
Diabetic Vascular Disease: Pathophysiological Mechanisms in the Diabetic
Milieu and Therapeutic Implications
Previous Brief Review in this Series:
Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM. RAGE axis: animal models and novel insights into the vascular complications of diabetes. 2004;24:13421349.
Type 2 diabetes is associated with significantly accelerated rates of macrovascular complications such as atherosclerosis. Emerging evidence now indicates that atherosclerosis is an inflammatory disease and that certain inflammatory markers may be key predictors of diabetic atherosclerosis. Proinflammatory cytokines and cellular adhesion molecules expressed by vascular and blood cells during stimulation by growth factors and cytokines seem to play major roles in the pathophysiology of atherosclerosis and diabetic vascular complications. However, more recently, data suggest that inflammatory responses can also be elicited by smaller oxidized lipids that are components of atherogenic oxidized low-density lipoprotein or products of phospholipase activation and arachidonic acid metabolism. These include oxidized lipids of the lipoxygenase and cyclooxygenase pathways of arachidonic acid and linoleic acid metabolism. These lipids have potent growth, vasoactive, chemotactic, oxidative, and proinflammatory properties in vascular smooth muscle cells, endothelial cells, and monocytes. Cellular and animal models indicate that these enzymes are induced under diabetic conditions, have proatherogenic effects, and also mediate the actions of growth factors and cytokines. This review highlights the roles of the inflammatory cyclooxygenase and 12/15-lipoxygenase pathways in the pathogenesis of diabetic vascular disease.
Evidence suggests that inflammatory responses in the vasculature can be elicited by small oxidized lipids that are components of oxidized low-density lipoprotein or products of the lipoxygenase and cyclooxygenase pathways of arachidonic and linoleic acid metabolism. This review evaluates these inflammatory and proatherogenic pathways in the pathogenesis of diabetic vascular disease.
Key Words: lipoxygenase diabetes diabetes complications inflammation lipids
This article has been cited by other articles:
![]() |
H. Yuan, L. Lanting, Z.-G. Xu, S.-L. Li, P. Swiderski, S. Putta, M. Jonnalagadda, M. Kato, and R. Natarajan Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes Am J Physiol Renal Physiol, August 1, 2008; 295(2): F605 - F617. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Gleissner, J. M. Sanders, J. Nadler, and K. Ley Upregulation of Aldose Reductase During Foam Cell Formation as Possible Link Among Diabetes, Hyperlipidemia, and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1137 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wen, J. Gu, G. E. Vandenhoff, X. Liu, and J. L. Nadler Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1933 - H1938. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Nikolic, M. C. Gong, J. Turk, and S. R. Post Class A Scavenger Receptor-mediated Macrophage Adhesion Requires Coupling of Calcium-independent Phospholipase A2 and 12/15-Lipoxygenase to Rac and Cdc42 Activation J. Biol. Chem., November 16, 2007; 282(46): 33405 - 33411. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Kanter, F. Johansson, R. C. LeBoeuf, and K. E. Bornfeldt Do Glucose and Lipids Exert Independent Effects on Atherosclerotic Lesion Initiation or Progression to Advanced Plaques? Circ. Res., March 30, 2007; 100(6): 769 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wen, J. Gu, S. K. Chakrabarti, K. Aylor, J. Marshall, Y. Takahashi, T. Yoshimoto, and J. L. Nadler The Role of 12/15-Lipoxygenase in the Expression of Interleukin-6 and Tumor Necrosis Factor-{alpha} in Macrophages Endocrinology, March 1, 2007; 148(3): 1313 - 1322. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-A. Karabina, I. Brocheriou, G. Le Naour, M. Agrapart, H. Durand, M. Gelb, G. Lambeau, and E. Ninio Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function FASEB J, December 1, 2006; 20(14): 2547 - 2549. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-l. Li, M. A. Reddy, Q. Cai, L. Meng, H. Yuan, L. Lanting, and R. Natarajan Enhanced Proatherogenic Responses in Macrophages and Vascular Smooth Muscle Cells Derived From Diabetic db/db Mice Diabetes, September 1, 2006; 55(9): 2611 - 2619. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Qi, R. M. van Dam, S. Liu, M. Franz, C. Mantzoros, and F. B. Hu Whole-Grain, Bran, and Cereal Fiber Intakes and Markers of Systemic Inflammation in Diabetic Women Diabetes Care, February 1, 2006; 29(2): 207 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zuccollo, C. Shi, R. Mastroianni, K. A. Maitland-Toolan, R. M. Weisbrod, M. Zang, S. Xu, B. Jiang, J. M. Oliver-Krasinski, A. J. Cayatte, et al. The Thromboxane A2 Receptor Antagonist S18886 Prevents Enhanced Atherogenesis Caused by Diabetes Mellitus Circulation, November 8, 2005; 112(19): 3001 - 3008. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Li, R. S. Dwarakanath, Q. Cai, L. Lanting, and R. Natarajan Effects of silencing leukocyte-type 12/15-lipoxygenase using short interfering RNAs J. Lipid Res., February 1, 2005; 46(2): 220 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman Antiinflammatory Properties of HDL Circ. Res., October 15, 2004; 95(8): 764 - 772. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |